

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca and according to acceptable standards of care

## PROTOCOL CODE: LYVENOB (Cycle 1)

(Page 1 of 2)		
DOCTOR'S ORDERS Wt_	kg	
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form		
DATE: To be given:	Cycle # 1	
<ul> <li>Low-medium TLS Risk- Days 1, 8, 15 chemo must be given on a Thursday</li> <li>High TLS Risk – chemo not restricted to a Thursday and consider inpatient admission</li> </ul>		
Delay treatment week(s)		
CBC & Diff day of treatment		
Day 1: May proceed with doses as written if within 72 hours ANC greater than or equal to 1.0 x 10 <sup>9</sup> /L, platelets greater than or equal to 25 x 10 <sup>9</sup> /L, total bilirubin less than or equal to 3 x ULN		
Day 2: May proceed with doses as written if within 24 hours ANC greater than or equal to 1.0 x 10 <sup>9</sup> /L, platelets greater than or equal to 25 x 10 <sup>9</sup> /L, chemistry normal		
Dose modification for: Hematology Other Toxicity		
Proceed with treatment based on blood work from		
Tumor Lysis Prophylaxis:         Patient to take own supply. RN/Pharmacist to confirm		
allopurinol 300 mg PO daily start at least 72 hours prior to first dose of oBINutuzumab		
Advise patient to drink 1.5 to 2 L of fluids daily starting 48 hours prior to first dose of oBINutuz Cycle 3 Day 1	umab and continue until	
PREMEDICATIONS for oBINutuzumab INFUSION:		
Patient to take supply of oral medications. RN/Pharmacist to confirm		
If ordered, ensure patient has taken steroid the day(s) prior to infusion.		
Days 1 and 2:		
60 minutes prior to infusion: <b>dexamethasone 20 mg</b> IV 30 minutes prior to infusion: <b>acetaminophen 650 to 975 mg</b> PO and <b>diphenhydrAMINE</b> 9	<b>50 mg</b> PO	
Days 8 and 15:		
If reaction to previous oBINutuzumab was Grade 3, or if lymphocyte count greater than Day 2 oBINutuzumab, then 60 minutes prior to treatment: dexamethasone 20 mg IV		
30 minutes prior to treatment: acetaminophen 650 mg to 975 mg PO and diphenhydrAMINE 50 mg PO		
**Have Hypersensitivity Reaction Tray and Protocol Available**		
TREATMENT:		
Day 1: oBINutuzumab 100 mg IV in 100 mL NS on Day 1.		
Administer over 4 hours at <b>25 mg/h</b> . Refer to protocol appendix for oBINutuzumab infusion rate titration table.		
Day 2:		
oBINutuzumab 900 mg IV in 250 mL NS on Day 2.		
Start at <b>50 mg/h</b> ; after 30 minutes, increase by 50 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.		
Cycle 1 Days 1 and 2: constant visual observation during dose increases and for 30 minutes after infusion completed. Vital signs not required unless symptomatic. Refer to protocol for resuming infusion following a reaction.		
If flushing, dyspnea, rigors, rash, pruritus, vomiting, chest pain, any other new acute discore existing symptoms occur, stop infusion and page physician.	mfort or exacerbation of any	
Days 8 and 15:		
oBINutuzumab 1000 mg IV in 250 mL NS on Days 8 and 15.		
If no infusion reaction or only Grade 1 infusion reaction in the previous infusion and final infusion rate was 100 mg/h or faster: Start at <b>100 mg/h</b> . Increase by 100 mg/h every 30 minutes until rate = 400 mg/h unless toxicity occurs. Refer to protocol appendix for oBINutuzumab infusion rate titration table.		
DOCTOR'S SIGNATURE:	SIGNATURE:	
DOULOR & SIGNALORE.		
	UC:	
BC Cancer Provincial Preprinted Order LYVENOB (Cycle 1) Created: 1 Feb 2022 Revised: 1 Mar 2025 (Premedications and rate clarified, observation, vitals,	and tests updated)	



Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at <u>www.bccancer.bc.ca</u> and according to acceptable standards of care

## PROTOCOL CODE: LYVENOB (Cycle 1)

(Page 2 of 2)

Date:	
RETURN APPOINTMENT ORDERS	
Return in <b>three</b> weeks or <u>weeks</u> for Doctor and Cycle 2.	
Note: Treatment dates for Cycle 1 Days 1, 8 and 15, and Cycle 2 Day 8 must be on a Thursday for Low-Medium TLS risk patients- refer to page 1 for TLS risk category	
For Cycle 1, book treatment on Day 1, Day 2, Day 8 and Day 15	
For Cycle 2, book treatment on Day 8 (i.e. 4 weeks from Cycle 1 Day 1)	
Prior to Cycle 1 Day 2: CBC & Diff, potassium, calcium, phosphate, uric acid, creatinine, LDH, albumin	
Prior to Cycle 2: CBC & Diff, potassium, calcium, phosphate, uric acid, creatinine, total bilirubin, ALT, LDH, albumin	
If clinically indicated:	
HBV viral load	
Other tests:	
Consults:	
See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: